TY - JOUR
T1 - Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life
AU - Kulisevsky, Jaime
AU - Santos García, Diego
AU - Deus Fonticoba, María Teresa de
AU - Paz González, J. M.
AU - Cores Bartolomé, Carlos
AU - Valdés Aymerich, L.
AU - Muñoz Enríquez, J. G.
AU - Suárez, E.
AU - Jesús, S.
AU - Aguilar Barberà, Miquel
AU - Pastor, P.
AU - Planellas, L. L.
AU - Cosgaya, Marina
AU - García Caldentey, J.
AU - Caballol, Nuria
AU - Legarda, Inés
AU - Hernández-Vara, Jorge
AU - Cabo-Lopez, Iria
AU - López Manzanares, L.
AU - Gonzalez-Aramburu, Isabel
AU - Ávila, Asunción
AU - Catalán, M. J.
AU - Nogueira, V.
AU - Puente, V.
AU - García Moreno, José Manuel
AU - Borrué, Carmen
AU - Solano Vila, B.
AU - Álvarez Sauco, María
AU - Vela, Lydia
AU - Escalante, Sonia
AU - Cubo, Esther
AU - Carrillo Padilla, Francisco
AU - Martínez-Castrillo, Juan Carlos
AU - Sánchez Alonso, P.
AU - Alonso Losada, M. G.
AU - López Ariztegui, Nuria
AU - Gastón, I.
AU - Blázquez Estrada, Marta
AU - Seijo, M.
AU - Rúiz Martínez, J.
AU - Valero, C.
AU - Kurtis, M.
AU - Fàbregues-Boixar i Nebot, Oriol de
AU - González-Ardura, J
AU - Ordás, C.
AU - López Díaz, L.
AU - Mir, P.
AU - Martinez-Martin, Pablo
AU - COPPADIS Study Group, None
PY - 2021
Y1 - 2021
N2 - In a degenerative disorder such as Parkinson's disease (PD), it is important to establish clinical stages that allow to know the course of the disease. Our aim was to analyze whether a scale combining Hoehn and Yahr's motor stage (H&Y) and the nonmotor symptoms burden (NMSB) (assessed by the nonmotor symptoms scale (NMSS)) provides information about the disability and the patient's quality of life (QoL) with regard to a defined clinical stage. Cross-sectional study in which 603 PD patients from the COPPADIS cohort were classified according to H&Y (1, stage I; 2, stage II; 3, stage III; 4, stage IV/V) and NMSB (A: NMSS = 0-20; B: NMSS = 21-40; C: NMSS = 41-70; D: NMSS ≥ 71) in 16 stages (HY.NMSB, from 1A to 4D). QoL was assessed with the PDQ-39SI, PQ-10, and EUROHIS-QOL8 and disability with the Schwab&England ADL (Activities of Daily Living) scale. A worse QoL and greater disability were observed at a higher stage of H&Y and NMSB (p < 0.0001). Combining both (HY.NMSB), patients in stages 1C and 1D and 2C and 2D had significantly worse QoL and/or less autonomy for ADL than those in stages 2A and 2B and 3A and 3B, respectively (p < 0.005; e.g., PDQ-39SI in 1D [ n = 15] vs 2A [ n = 101]: 28.6 ± 17.1 vs 7.9 ± 5.8; p < 0.0001). The HY.NMSB scale is simple and reflects the degree of patient involvement more accurately than the H&Y. Patients with a lower H&Y stage may be more affected if they have a greater NMS burden.
AB - In a degenerative disorder such as Parkinson's disease (PD), it is important to establish clinical stages that allow to know the course of the disease. Our aim was to analyze whether a scale combining Hoehn and Yahr's motor stage (H&Y) and the nonmotor symptoms burden (NMSB) (assessed by the nonmotor symptoms scale (NMSS)) provides information about the disability and the patient's quality of life (QoL) with regard to a defined clinical stage. Cross-sectional study in which 603 PD patients from the COPPADIS cohort were classified according to H&Y (1, stage I; 2, stage II; 3, stage III; 4, stage IV/V) and NMSB (A: NMSS = 0-20; B: NMSS = 21-40; C: NMSS = 41-70; D: NMSS ≥ 71) in 16 stages (HY.NMSB, from 1A to 4D). QoL was assessed with the PDQ-39SI, PQ-10, and EUROHIS-QOL8 and disability with the Schwab&England ADL (Activities of Daily Living) scale. A worse QoL and greater disability were observed at a higher stage of H&Y and NMSB (p < 0.0001). Combining both (HY.NMSB), patients in stages 1C and 1D and 2C and 2D had significantly worse QoL and/or less autonomy for ADL than those in stages 2A and 2B and 3A and 3B, respectively (p < 0.005; e.g., PDQ-39SI in 1D [ n = 15] vs 2A [ n = 101]: 28.6 ± 17.1 vs 7.9 ± 5.8; p < 0.0001). The HY.NMSB scale is simple and reflects the degree of patient involvement more accurately than the H&Y. Patients with a lower H&Y stage may be more affected if they have a greater NMS burden.
U2 - 10.1155/2021/8871549
DO - 10.1155/2021/8871549
M3 - Article
C2 - 34094501
SN - 2042-0080
VL - 2021
JO - Parkinson's Disease
JF - Parkinson's Disease
ER -